Xiao-E Yan

发表

Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.

Qingsong Liu, C. Yun, Zhenquan Hu, 2018, European journal of medicinal chemistry.

Structural basis of mutant-selectivity and drug-resistance related to CO-1686.

C. Yun, Ling Liang, Su-Jie Zhu, 2017, Oncotarget.

Structural pharmacological studies on EGFR T790M/C797S.

C. Yun, Su-Jie Zhu, L. Kong, 2017, Biochemical and biophysical research communications.

Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.

Jing Liu, Cheng Chen, Wei Wang, 2017, Journal of medicinal chemistry.

Structural insights into drug development strategy targeting EGFR T790M/C797S

Sheng-yong, Sheng-yong Yang, C. Yun, 2018, Oncotarget.

Structural basis of AZD9291 selectivity for EGFR T790M.

D. Shaw, Y. Shan, H. Choi, 2020, Journal of medicinal chemistry.

Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode

Qingsong Liu, C. Yun, Hong Wu, 2017, Oncotarget.

Structural and biochemical studies of the PDGFRA kinase domain.

Yuxin Yin, C. Yun, Ling Liang, 2016, Biochemical and biophysical research communications.

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation

N. Gray, Qingsong Liu, Jinhua Wang, 2016, Oncotarget.

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

N. Gray, Qingsong Liu, Jinhua Wang, 2015, Oncotarget.

A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties.

Yong Xu, Lin-jiang Tong, C. Yun, 2017, European journal of medicinal chemistry.

Structural pharmacological studies on EGFR T790M/C797S.

C. Yun, Su-Jie Zhu, L. Kong, 2017, Biochemical and biophysical research communications.

Structural basis of mutant-selectivity and drug-resistance related to CO-1686

H. Choi, C. Yun, Ling Liang, 2017, Oncotarget.

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

N. Gray, Qingsong Liu, Jinhua Wang, 2015, Oncotarget.